Enobia drug gets fast track status
The FDA has granted Fast Track status to Enobia Pharma's ENB-0040 for the treatment of hypophosphatasia (HPP). There are currently no treatments for the rare bone disease. Enobia release
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Chronic Pain Is Relieved by Cell Transplantation in Lab Study
- Drug-vaccine combo better for breast cancer
- Marked for destruction: Newly developed compound triggers cancer cell death
- Orthofix International Completes Divestiture of Sports Medicine Business Unit
- ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
- More Press Releases
Featured Jobs
-
Director, Pharmacovigilance and Drug Safety
TESARO - Waltham, MA -
Director, Regulatory Affairs
Tesaro - Waltham, MA -
Program Lead - Scientific Information Architecture & Search
Merck - Kenilworth, NJ -
Regulatory Scientist Assistant III (Senior) Job
Yoh - Kenilworth, NJ, USA -
Oncology Knowledge Lead
Merck - Boston, MA
Comments